Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 105

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 105
---
 %, to approximately $259 thousand for the six months ended June
30, 2025, compared to $297 thousand for the six months ended June 30, 2024. The decrease resulted mainly from a decrease in professional
fees.

Finance income (expense), net

Finance income decreased by approximately $8,123 thousand, or
152.3%, to approximately finance expenses, net of $2,789 thousand for the six months ended June 30, 2025, compared to finance income,
net of $5,334 thousand for the six months ended June 30, 2024. The decrease resulted mainly from a decrease in a fair value revaluation
income of convertible notes and warrants.

Net loss

Net loss increased by
approximately $10,435 thousand to a net loss of approximately $3,228 thousand for the six months ended June 30, 2025, compared
to a net income of $7,207 thousand for the six months ended June 30, 2024. The increase in net loss was mainly the result
of an increase in finance expense from fair value revaluation and from decrease in income recorded in 2024 as part of research and development
expenses which were a result of Horizon 2020 Program approval.

Year Ended December 31, 2024 Compared to Year Ended December 31, 2023

Research and development expenses

Research and development
expenses decreased by approximately $2,450 thousand or 303.9%, to approximately income of $1,644 thousand for the year ended December
31, 2024, compared to $806 thousand for the year ended December 31, 2023. The decrease resulted mainly from the Horizon 2020 Grant, and
from a decrease in subcontractors’ expenses due to lower research and development activity during 2024 partly offset by an increase
in expenses related to CSL Settlement, which was recorded during 2024.

General and administrative expenses

General and administrative
expenses decreased by approximately $413 thousand, or 36.7%, to approximately $712 thousand for the year ended December 31, 2024, compared
to approximately $1,125 thousand for the year ended December 31, 2023. The decrease resulted mainly from a decrease in professional fees
due to the recognition of prepaid issuance costs associated with the former initial public offering process, recognized as expense following
the entry into the business combination agreement, or BCA, with OceanTech Corp. during the second quarter